Eyecelerator@ASCRS

Thursday, July 22, 2021
11:30 a.m. – 5:30 p.m. PT

 

Mandalay Bay South Convention Center, Las Vegas
Oceanside Ballroom CD, Level 2

Bring the future of ophthalmology into focus. 

$300: General Registration | $150: AAO/ASCRS Member | $50: Physician In Training

CONFERENCE PROGRAM

Registration + Lunch

11:30 a.m. –
12:45 p.m.

Check in and enjoy a bite to eat.

Welcome!

12:35 -1:00 p.m. a.m.

What is Eyecelerator?
David W. Parke II, MD, Steve Speares and Gil Kliman, MD 

Conference Overview

Eric D. Donnenfeld, MD and Jim Mazzo

Mini Keynote: State of the Financial Markets
Chris Cooley, CFA
Managing Director, Stephens Inc.

1:00 – 1:15 p.m.

Take a peek behind the investment banking curtain for a critical assessment of the challenges and opportunities in today's shifting health care markets.

Industry Spotlight, Part I

1:15 – 1:45 p.m.

A panel of global strategic executives examines the impact of COVID-19 on ophthalmic companies and where they'll focus resources in the coming years.  


Moderator: Richard L. Lindstrom, MD
 

Aerie: Tom Mitro, President and Chief Operating Officer
Alcon: David Endicott, Chief Executive Officer
BVI: Shervin Korangy, President & CEO
Glaukos: Thomas Burns, CEO and President  
Zeiss: Euan Thomson, President Ophthalmic Devices and Head of Digital

Ophthalmic Consolidation: What it Means to You

1:45 – 2:15 p.m.

Get an informed perspective on the challenges and opportunities surrounding industry consolidation from a variety of viewpoints, including hospitals, private practice, CMS and equity investments. 

Moderator: Kerry Solomon, MD
 
Panelists:
Hospital: Rick Gannotta, DHA, FACHE
Private Practice: Ruth D. Williams, MD
Private Equity: Anthony Hayes
CMS Specialist: Joel V. Brill, MD

Presbyopia: Everybody gets it... but can it be fixed?  

2:15 – 2:55 p.m.

We are on the cusp of pharmacologic treatments for presbyopia and competition is heating up.  So put down your readers and join us for a look at the companies innovating in one of the world's largest ophthalmic markets. 

 

Company Showcases

  1. Allergan, an AbbVie Company: Michael R. Robinson, MD

  2. Eyenovia: Michael Rowe

  3. Ocuphire: Mina Sooch

  4. Orasis: Elad Kedar

  5. LENZ Therapeutics: Eef Schimmelpennink

  6. Visus: Ben Bergo

Panel Discussion

Moderator: John P. Berdahl, MD

 

Panelists:

Preeya K. Gupta, MD

John A. Hovanesian, MD

Gil Kliman, MD

Vance Thompson, MD

Networking Break

2:55 – 3:25 p.m.

Enjoy refreshments and connect with your colleagues.

Dry Eye: The Need For Innovation

3:25 – 4:15 p.m.

Dry eye represents one of the biggest unmet needs in eye care. Hear from the innovation companies developing new treatments with a variety of MOAs.

 

Company Showcases

  1. Allegro: Vicken Karageozian, MD

  2. Azura: Charles Bosworth, PhD

  3. Oculis: Riad Sherif

  4. Oysterpoint: Jeffrey Nau, PhD, MMS

  5. Palatin: Carl Spana, PhD

  6. Surface: Kamran Hosseini, MD, PhD

  7. Tarsus: Aziz Mottiwala

Panel Discussion

Moderator: Edward J. Holland, MD

 

Panelists:

Robert Dempsey

Marjan Farid, MD

Nicole R. Fram, MD

Francis S. Mah, MD

Industry Spotlight, Part II

4:15 – 4:45 p.m.

A panel of global strategic executives examines the impact of COVID-19 on ophthalmic companies and where they'll focus resources in the coming years.  

 

Moderator: Cathleen M. McCabe, MD

  • Allergan, an AbbVie Company: Jag Dosanjh, SR. VP, Specialty Therapeutics

  • Bausch + Lomb: Joseph Papa, Chief Executive Officer

  • Johnson & Johnson: Warren Foust, Worldwide President, Surgical

  • STAAR Surgical: Caren Mason, President & CEO

New Glaucoma Treatments

4:45 – 5:25 p.m.

Meet the companies pioneering innovative new treatments within the specialty. 

 

Company Showcases

  1. Avisi: Rui Jing Jiang

  2. ELT Sight: Matilda Parente, MD

  3. Equinox:  John P. Berdahl, MD

  4. ViaLase: Tibor Juhasz

Panel Discussion

Moderators: Nathan M. Radcliffe, MD and Thomas W. Samuelson, MD

Panelists:  

Ron Bache

Leon Herndon, MD

Sarah Van Tassel, MD

Robert Warner

Thanks for Attending!

5:25 – 5:30 p.m.

Eric D. Donnenfeld, MD and Jim Mazzo